Notable Reporting: After Today’s Big Increase, Is Aralez Pharmaceuticals Inc’s Near-Term Analysis Positive?

Notable Reporting: After Today's Big Increase, Is Aralez Pharmaceuticals Inc's Near Term Analysis Positive?

The stock of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) is a huge mover today! About 288,676 shares traded hands. Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has risen 2.19% since March 15, 2016 and is uptrending. It has underperformed by 3.30% the S&P500.
The move comes after 6 months positive chart setup for the $304.68 million company. It was reported on Oct, 18 by Barchart.com. We have $14.30 PT which if reached, will make NASDAQ:ARLZ worth $603.27M more.

Analysts await Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) to report earnings on November, 14. They expect $-0.32 EPS, down 28.00% or $0.07 from last year’s $-0.25 per share. After $-0.27 actual EPS reported by Aralez Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 18.52% negative EPS growth.

According to Zacks Investment Research, “Aralez Pharmaceuticals Inc. is a global specialty pharmaceutical company. They acquire, develop and commercialize products primarily in cardiovascular, pain and other specialty areas.”

More notable recent Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) news were published by: Investorplace.com which released: “Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal” on October 04, 2016, also Fool.com with their article: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” published on August 01, 2016, Fool.com published: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” on September 15, 2016. More interesting news about Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) were released by: Marketwatch.com and their article: “/quotes/zigman/3870025/realtime” published on February 12, 2016 as well as Seekingalpha.com‘s news article titled: “Aralez Pharmaceuticals Inc.: Upcoming Catalysts Create Tremendous Upside” with publication date: August 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment